Clinical Trial: NCT03097770
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Chinese PLA General Hospital |
| Information Provided By: | Chinese PLA General Hospital |
| Last Update Posted: | 2020-09-02 |
Study Overview
Brief Summary
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to chemotherapy.
Official Title
Conditions
Intervention / Treatment
- Biological: anti-CD19/20-CAR vector-transduced T cells
Other Study ID Numbers
- CHN-PLAGH-BT-020
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Chinese PLA General Hospital |
| Information Provided By: | Chinese PLA General Hospital |
| Last Update Posted: | 2020-09-02 |
Study Overview
Brief Summary
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to chemotherapy.
Official Title
Conditions
Intervention / Treatment
- Biological: anti-CD19/20-CAR vector-transduced T cells
Other Study ID Numbers
- CHN-PLAGH-BT-020